Zilin Xu

Ms. Zilin Xu

orcid

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2026 in Genes & Diseases
Verified
Journal Article
Open access
LJLingao Ju
Lingao Ju
GWGang Wang
Gang Wang
ZXZilin Xu
Zilin Xu
WXWan Xiang
Wan Xiang
HPHongwei Peng
Hongwei Peng
YXYu Xiao
Yu Xiao

12 June 2026 in Organoids
Verified
Journal Article
Open access
PDF file
JSJia Shang
Jia Shang
CXCaixia Xia
Caixia Xia
ZXZilin Xu
Zilin Xu
STSheng Tu
Sheng Tu
GLGang Li
Gang Li
KQKaiyu Qian
Kaiyu Qian
Patient-derived organoids (PDOs) provide ex vivo functional models that capture tumor drug-response patterns across multiple cancer types. Organoid drug sensitivity testing (ODST) has accumulated supportive evidence in single-tumor studies, yet it lacks a pan-cancer biostatistical framework that can support multi-cancer clinical decision-making. This article presents a pan-cancer ODST validation framework that integrates evidence synthesis, regulatory mapping, and adaptive trial design. The framework specifies analytical-performance standards, a three-stage validation architecture, and an explicit cross-tumor portability coefficient that quantifies the transferability of validated evidence among cancer types. Implementation barriers, including heterogeneous tissue-collection standards, variable establishment success, immunotherapy modeling limitations, and regulatory misalignment, are identified, and corresponding mitigation strategies are described. The framework supports a structured pathway from analytical validity to clinical utility for ODST across solid-tumor indications.

18 November 2026 in Medical Ethics and Bioethics
Verified
Journal Article
Open access
PDF file
ZXZilin Xu
Zilin Xu
CXCaixia Xia
Caixia Xia
GLGang Li
Gang Li
SLShenjuan Li
Shenjuan Li
STSheng Tu
Sheng Tu
GWGang Wang
Gang Wang
Electronic informed consent (eConsent) reached through a quick response (QR) code is attractive where messaging applications such as WeChat are in daily use. A QR code only gives access to a process. It does not determine how identity is attributed, how questions are answered, how a choice is recorded, or where records are kept. This Perspective analyzes QR-accessed eConsent for research on urine-derived induced pluripotent stem cells (UDiPSCs). Urine collection is a minor physical burden, but the derived cell lines can be maintained indefinitely, carry the donor’s genome and be shared. We identify three tensions that this setting sharpens: attribution of a decision to a person against data minimization, participant autonomy over durable cell lines, and authorization of uses that cannot be foreseen. We separate considerations that depend on the technical destination of the QR code from those that apply to any digital system. We distinguish applicable legal requirements, ethical guidance and proposed implementation measures, drawing on Chinese rules on research ethics review, human genetic resources, personal information protection and electronic signatures. Six recommendations are offered for institutional review, together with suggested evaluation criteria. They have not been empirically validated. The ethical acceptability of consent depends on the protocol and the consent process, not on whether consent is recorded on paper or reached through WeChat.